Ertugliflozin Delays Insulin Initiation and Reduces Insulin Dose Requirements in Patients With Type 2 Diabetes: Analyses From VERTIS CV

CONTEXT: VERTIS CV evaluated the cardiovascular safety of ertugliflozin in patients with type 2 diabetes and atherosclerotic cardiovascular disease (ASCVD). OBJECTIVE: The aim of these analyses was to assess the insulin requirements of VERTIS CV patients over the trial duration. METHODS: Patients re...

Descripción completa

Detalles Bibliográficos
Autores principales: Dagogo-Jack, Samuel, Frederich, Robert, Liu, Jie, Cannon, Christopher P, Shi, Harry, Cherney, David Z I, Cosentino, Francesco, Masiukiewicz, Urszula, Gantz, Ira, Pratley, Richard E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Clinical Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10348468/
https://www.ncbi.nlm.nih.gov/pubmed/36702781
http://dx.doi.org/10.1210/clinem/dgac764

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10348468/
https://www.ncbi.nlm.nih.gov/pubmed/36702781
http://dx.doi.org/10.1210/clinem/dgac764

Ejemplares similares